SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

CymaBay Therapeutics, Inc. CBAY NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

CymaBay Therapeutics, Inc. (CBAY) is a Biotechnology company in the Healthcare sector, currently trading at $32.48. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $31M, +0%/yr average growth. Net income is $105M (loss), growing at -35.8%/yr. Net profit margin is -339.1% (negative). Gross margin is 97.8% (+0 pp trend).

Balance sheet: total debt is $114M against $292M equity (Debt-to-Equity (D/E) ratio 0.39, conservative). Current ratio is 10.96 (strong liquidity). Debt-to-assets is 26.3%. Total assets: $435M.

Analyst outlook: 11 / 23 analysts rate CBAY as buy (48%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

CBAY SharesGrow Score Overview

34/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 58/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CBAY

No analyst coverage available for this stock.

CBAY: +0%/yr revenue is, -35.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet CBAY: Debt-to-Equity (D/E) ratio 0.39 (conservative), Current ratio is 10.96 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CBAY: Gross margin is 97.8% (+0 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.

View details →

Analyst outlook: 11 / 23 analysts rate CBAY as buy (48%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CBAY: Net profit margin is -339.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range7.261-32.5

Volume8.35M

Avg Volume (30D)3.94M

Market Cap$3.73B

Beta (1Y)0.32

Share Statistics

EPS (TTM)-0.99

Shares Outstanding$106.2M

IPO Date2014-02-03

Employees101

CEOSujal A. Shah

Financial Highlights & Ratios

Revenue (TTM)$31.07M

Gross Profit$30.39M

EBITDA$-85.74M

Net Income$-105.37M

Operating Income$-101.68M

Total Cash$394.26M

Total Debt$114.49M

Net Debt$-92.04M

Total Assets$434.69M

Price / Earnings (P/E)-32.8

Price / Sales (P/S)119.98

Analyst Forecast

Rating ConsensusHold

Analysts Covering23

Buy 48% Hold 52% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS23257D1037

Price Chart

CBAY

CymaBay Therapeutics, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

7.26 52WK RANGE 32.50

People Also View

Karuna Therapeutics, Inc.

Madrigal Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

Viking Therapeutics, Inc.

Kiniksa Pharmaceuticals, Ltd.

Structure Therapeutics Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message